Aeglea BioTherapeutics Investor Presentation Deck

SPY001 summary SPYRE 1000 COMPARABLE IN VITRO PERFORMANCE TO VEDOLIZUMAB 晋 HTDO PK MODELLING SUPPORTS Q8-12W SC DOSING; UPSIDE POTENTIAL FOR GREATER INDUCTION EFFICACY DEVELOPING PATIENT SELECTION APPROACHES TO IDENTIFY RESPONDERS INTERIM PHASE 1 PK DATA EXPECTED YE2024 19

View entire presentation